Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Alnylam Named #1 Largest Employer in MA for 2021 by The Boston Globe

December 2, 2021

Alnylam Pharmaceuticals

That we've been part of The Boston Globe's Top Places to Work list since 2015 is a point of particular pride for Alnylam, because since the list is based on employee survey data, we see it as an strong indicator of the strength of our company culture and signal that our employees feel respected, valued and that they believe in our mission. Our seventh year in row (and eighth year overall) also comes with two new distinctions - the ranking of #1 employer in the "Largest Companies" category (>1,000 employees) and the highest ranked life sciences company on this year's list in any category. See the full list here.

At Alnylam, we are changing the way disease is treated through the pursuit of innovative science, and that is only possible with a remarkable team. Despite the ongoing challenges of 2021, our colleagues banded together to find creative ways to continue to innovate, collaborate, and deliver on behalf of the patients that depend on us. Our run of seven years in a row is a testament to that while our pioneering science is our foundation, our people are truly what makes Alnylam amazing.” – John Maraganore, Ph.D., CEO of Alnylam

The Top Places to Work survey is completed by more than 80,000 employees, across 363 different companies in Massachusetts. They complete an anonymous, research-backed survey assessing categories such as their company’s direction, execution, connection, communication, management, work, pay and benefits. The list spotlights companies that support employees both in and out of the office, including caregiving, mental health, and other out-of-office needs. This recognition comes on the heels of Alnylam’s recent inclusion on Science magazine’s Top Employer list for the third consecutive year and being named a Fast Company Best Workplace for Innovators for 2021.

This year, winners share several key traits that have come into focus for employers as a result of the global pandemic, including more flexibility to work remotely, employees' mental health and a focus on diversity, equity and inclusion (DE&I) initiatives.  On this last point, we're especially proud that our efforts were further detailed by The Boston Globe in an article focusing on how companies are "putting in the real work" of making diversity, equity and inclusion part of their company culture. 

Read the entire Boston Globe Top Places to Work 2021 feature here. We invite you to learn more about our award-winning culture and career opportunities available at Alnylam.

Tags

Careers & Culture, Articles, DE&I, Awards, Boston Globe Top Places to Work, Careers, Our Culture

Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site